

September 19, 2022

Elisa Leune The Protein Brewery B.V. Goeseelsstraat 10 4817 MV Breda, Netherlands

Sent via email to: elisaleune@theproteinbrewery.nl

Dear Petitioner:

Your submission requesting that the Commissioner of Food and Drug review the evidence that discusses the mechanism of action by which and the evidence for (1-3)(1-6) β -glucan consumption and its beneficial effect on immunomodulation was received and processed under CFR 10.30 by this office on 09/19/2022.

It was assigned docket number FDA-2022-P-2287. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note, the acceptance of the petition for filing is a procedural matter and in no way reflects the Agency's decision on the substantive merits of the petition.

Sincerely,

Karen Malvin Acting Director Dockets Management Staff FDA/Office of Operations (OO)

cc: Tufts University, Friedman School of Nutrition Science and policy (maha@nutritionsustainability.com)